These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 37407064)

  • 1. Effects of volume-based procurement policy on the usage and expenditure of first-generation targeted drugs for non-small cell lung cancer with EGFR mutation in China: an interrupted time series study.
    Wang X; Huang H; Sun Y; Zhu Z; Jiang B; Yang L
    BMJ Open; 2023 Jul; 13(7):e064199. PubMed ID: 37407064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of China's National Volume-Based Procurement on Drug Procurement Price, Volume, and Expenditure: An Interrupted Time Series Analysis in Tianjin.
    Zhao B; Wu J
    Int J Health Policy Manag; 2023; 12():7724. PubMed ID: 38618801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of "4 + 7" volume-based drug procurement on the volume, expenditures, and daily costs of antihypertensive drugs in Shenzhen, China: an interrupted time series analysis.
    Yang Y; Tong R; Yin S; Mao L; Xu L; Hao S; Mao Z
    BMC Health Serv Res; 2021 Nov; 21(1):1275. PubMed ID: 34823516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of National Volume-Based Procurement on the Procurement Volumes and Spending for Antiviral Medications of Hepatitis B Virus.
    Yuan J; Lu ZK; Xiong X; Lee TY; Huang H; Jiang B
    Front Pharmacol; 2022; 13():842944. PubMed ID: 35734415
    [No Abstract]   [Full Text] [Related]  

  • 5. Trends of Negotiated Targeted Anticancer Medicines Use in China: An Interrupted Time Series Analysis.
    Huang C; Ung COL; Wushouer H; Bai L; Li X; Guan X; Shi L
    Int J Health Policy Manag; 2022 Aug; 11(8):1489-1495. PubMed ID: 34273922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impacts of national volume-based drug procurement policy on the utilization and costs of antihypertensive drugs in a Chinese medicine hospital: an interrupted time series analysis of 5138 patients.
    Shang L; Cheng Y; Zhou J; Bao Y; Kong D; Huang R; Chen Y; Wang H; Gu N; Ma A
    Front Pharmacol; 2024; 15():1302154. PubMed ID: 38389928
    [No Abstract]   [Full Text] [Related]  

  • 7. Effects of removing reimbursement restrictions on targeted therapy accessibility for non-small cell lung cancer treatment in Taiwan: an interrupted time series study.
    Hsu JC; Wei CF; Yang SC
    BMJ Open; 2019 Mar; 9(3):e022293. PubMed ID: 30878976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impacts of Chinese drug volume-based procurement policy on the use of policy-related antibiotic drugs in Shenzhen, 2018-2019: an interrupted time-series analysis.
    Yang Y; Chen L; Ke X; Mao Z; Zheng B
    BMC Health Serv Res; 2021 Jul; 21(1):668. PubMed ID: 34238290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trends in accessibility of negotiated targeted anti-cancer medicines in Nanjing, China: An interrupted time series analysis.
    Liu Y; Yi H; Fang K; Bao Y; Li X
    Front Public Health; 2022; 10():942638. PubMed ID: 35937254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impacts of National Drug Price Negotiation on Expenditure, Volume, and Availability of Targeted Anti-Cancer Drugs in China: An Interrupted Time Series Analysis.
    Sun Y; Zhu Z; Zhang J; Han P; Qi Y; Wang X; Yang L
    Int J Environ Res Public Health; 2022 Apr; 19(8):. PubMed ID: 35457445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of the national volume-based procurement policy on the use of policy-related drugs in Nanjing: an interrupted time-series analysis.
    Wang X; He X; Zhang P; Zhang M; Ma R; Dai R; Li X
    Int J Equity Health; 2023 Sep; 22(1):200. PubMed ID: 37770924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patients' attitudes towards switching to national volume-based procurement (NVBP) Drugs-a qualitative investigation in Wuhan, China.
    Tao J; Li S; Xu Q; Gong S; Zeng F
    BMC Health Serv Res; 2023 Jan; 23(1):62. PubMed ID: 36670463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
    Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of the National Centralized Drug Procurement Policy (4 + 7 policy) on the drug expenditures of patients treated in outpatient and emergency departments in a large tertiary level-A hospital in China: A single centre, interrupted time series.
    Lan T; Guan L; Pang X; Li X; Yu Q
    J Clin Pharm Ther; 2022 Jan; 47(1):104-111. PubMed ID: 34668203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can locally developed me-too drugs aid price negotiation? An example of cancer therapies from China.
    Luo Z; Gyawali B; Han S; Shi L; Guan X; Wagner AK
    Semin Oncol; 2021 Apr; 48(2):141-144. PubMed ID: 33875231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of first-line treatments for advanced epidermal growth factor receptor-mutant non-small cell lung cancer patients.
    Li WQ; Li LY; Chai J; Cui JW
    Cancer Med; 2021 Mar; 10(6):1964-1974. PubMed ID: 33626238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cost of total hip arthroplasty: compare the hospitalization costs of national centralized procurement and national volume-based procurement.
    Fan Y; Xu Q; Jin G; Jiang L; Wang C
    Front Public Health; 2024; 12():1383308. PubMed ID: 39040867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations.
    Liang W; Wu X; Fang W; Zhao Y; Yang Y; Hu Z; Xue C; Zhang J; Zhang J; Ma Y; Zhou T; Yan Y; Hou X; Qin T; Dinglin X; Tian Y; Huang P; Huang Y; Zhao H; Zhang L
    PLoS One; 2014; 9(2):e85245. PubMed ID: 24533047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of Osimertinib as First-line Treatment and Sequential Therapy for EGFR Mutation-positive Non-small Cell Lung Cancer in China.
    Cai H; Zhang L; Li N; Chen S; Zheng B; Yang J; Weng L; Liu MB
    Clin Ther; 2019 Feb; 41(2):280-290. PubMed ID: 30639208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of icotinib in the treatment of advanced EGFR mutation-positive nonsmall cell lung cancer: A meta-analysis of randomized controlled trials.
    Li D; Yao L; Xu L; Li W; Che Y
    Medicine (Baltimore); 2022 Dec; 101(48):e32164. PubMed ID: 36482605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.